- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Reston Today
By the People, for the People
Journal of Nuclear Medicine Publishes New Research
Studies cover PET/CT scans, FAP-targeted radiotherapy, AI tumor measurement, and PSMA radioligand therapy
Published on Mar. 7, 2026
Got story updates? Submit your updates here. ›
The Journal of Nuclear Medicine has published new research ahead-of-print, including studies on using PET/CT scans to uncover causes of fever, a first-in-human case series on an experimental radiopharmaceutical targeting fibroblast activation protein, an AI tool that can match expert performance in measuring lymphoma tumor burden, and outcomes of PSMA-targeted radioligand therapy in aggressive-variant prostate cancer.
Why it matters
These studies showcase the latest advancements in nuclear medicine, molecular imaging, and precision cancer treatments that can help improve patient outcomes. The research highlights the ongoing efforts to develop more accurate diagnostic tools and personalized therapies for complex medical conditions.
The details
The new JNM studies cover a range of topics in nuclear medicine and molecular imaging. The PET/CT scan study examined how well the imaging technique can detect hidden infections, inflammatory diseases, or cancers in patients with fevers of unknown origin. The first-in-human case series looked at the experimental radiopharmaceutical 177Lu-RTX-2358, which targets fibroblast activation protein in advanced solid tumors. Researchers also tested an AI model designed to automatically measure total metabolic tumor volume in lymphoma using PET/CT, finding it can match expert performance. Finally, the study on PSMA radioligand therapy evaluated outcomes in patients with aggressive-variant prostate cancer, a high-risk form of metastatic disease.
- The new research was published ahead-of-print by The Journal of Nuclear Medicine on March 6, 2026.
The players
The Journal of Nuclear Medicine (JNM)
JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics.
Society of Nuclear Medicine and Molecular Imaging
An international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
The takeaway
The new research published in the Journal of Nuclear Medicine highlights the ongoing advancements in nuclear medicine and molecular imaging technologies that are improving diagnosis, treatment planning, and patient outcomes for complex medical conditions. These studies showcase the potential of PET/CT scans, targeted radiotherapies, and AI-powered tumor analysis to transform the field of precision medicine.
